Photo: ‚feelimage/Matern‘
Photo: ‚feelimage/Matern‘
Michael Berger
Postdoctoral researcher
in Health Economics and Health Policy
Medical University of Vienna
Contact: michael.a.berger[at]meduniwien.ac.at
I am a Post Doc Researcher (career track) at the Medical University of Vienna and Post Doc Fellow at the Institute for Advanced Studies in Vienna. I received a doctorate at the Vienna University of Economics and Business.
My research areas are health economics, health policy and health inequality. My work focuses on the institutional causes behind disparities in healthcare utilisation and their implications for the financial sustainability and equity of healthcare systems. My work includes collaborations in demographic research and occasional within-trial health economic evaluations.
Update: I am visiting researcher at the The Max Planck – University of Helsinki Center for Social Inequalities in Population Health (MaxHel Center) from 1 April 2025 to 31 March 2026. The research stay is funded by the Erwin Schrödinger programme of the Austrian Science Fund (FWF) [grant no. J 4904-G].
My current working papers, work in progress and selected peer-review publications are listed below.
Measuring historical social inequalities in life span in 20th-century Vienna using data from tombstones
(with Susanne Mayer, Moritz Oberndorfer & Theresa Samek)
Mortgages, household economic resilience and health (2025-2026)
Grant: Austrian Science Fund (FWF). Role: PI
Buy or rent? Mental health risk trade-offs from involuntary job loss between homeownership and mortgage debt in Finland
(with Joan Damiens & Pekka Martikainen)
STREAMLINE (2023-2025)
Grant: Vienna Science and Technology Fund (WWTF); Role: Co-PI
Spatio-temporal trends in mental health-related outpatient prescriptions in Austria
(with Matthew Boersig-McPhillips, Susanne Mayer & Judit Simon)
Equity-aspects in mental health-related service provision in Vienna
(with Matthew Boersig-McPhillips, Susanne Mayer & Judit Simon)
Managing the substantial number of medications of end-of-life patients can be challenging for treating physicians and incur unnecessary costs for the healthcare system. Digital Clinical Decision Support Systems (CDSS) promise to optimize medication management for patients, but their economic aspects have not been studied in detail. This study prospectively evaluated the economic aspects of the CDSS-OPTIMED implemented in the multi-centre iLIVE project with ten participating sites in the Nether-lands, Sweden, Switzerland. The study used a before-and-after study design with a primary endpoint at four-week follow-up. 98 out of 236 recruited patients (59 in the control- and 39 in the intervention phase) reported complete data and were included in the economic evaluation. We evaluated patients’ self-reported health-related quality of life (HRQoL), broader well-being and healthcare costs. We used a combination of descriptive statistics, graphical analysis and multilevel, multivariable linear regression analyses. We find a statistically significant improvement of HRQoL measures in the CDSS-OPTIMED intervention group. However, the result is sensitive to outliers and does not extend to broader well-being measures. We do not find any differences in healthcare costs between the groups. The economic evaluation of the CDSS-OPTIMED in the iLIVE project cannot provide conclusive evidence about its cost-effectiveness. Beside data limitations, most of the control phase fell into the COVID-19 pandemic adding contextual dependency to the results. Despite these limitations, the econom-ic evaluation provides important lessons for future economic evaluations in palliative and end-of-life care settings.
People with bipolar disorders (BD) frequently experience depressive symptoms that do not respond to available treatment options. The resulting burden for people with BD and society is substantial. This study sought to explore the cost-effectiveness of pramipexole in combination with mood stabilisers for people with treatment-resistant bipolar disorder (TRBD). We calculated mean incremental cost ratios (ICER) of pramipexole compared to placebo over 12 and 48 weeks from health and social care (NHS + PSS) and societal perspectives for 36 participants with TRBD. Quality-adjusted life years (QALY) were captured with the EQ-5D-5L as the primary outcome measure. We used capability well-being measures (ICECAP-A, OxCAP-MH) to assess the robustness of the results and multiple imputation and bootstrapping to address missing data and small sample size. We found that pramipexole is more effective and cost-saving from the NHS + PSS perspective. The probability of being cost-effective at £30,000/QALY gained was 70 % (12 weeks) and 90 % (48 weeks). From the societal perspective, pramipexole was more effective but also more expensive with lower probability of cost-effectiveness (33 % at 12 weeks and 47 % at 48 weeks). Uncertainty around the mean ICERs was substantial due to the small sample size. The PAX-BD trial was conducted during the COVID-19 pandemic and terminated early, resulting in a limited generalizability of resource use outside the pandemic context and a small sample size. Pramipexole is a cost-effective treatment option for TRBD from the NHS + PSS perspective, with statistically significant increases in health-related quality of life and capability well-being over extended periods.
Medical practice variation is a useful indicator for policymakers aiming to improve the efficiency of healthcare delivery. Previous studies have shown strong regional variation in healthcare utilisation in Austria, which seems to be a by-product of regionalised institutional rules and healthcare service mix rather than epidemiology. We use a set of routine municipality-level healthcare data on hospital admissions for depressive episodes of adult Austrian patients from 2009 to 2014 to examine spatial patterns in healthcare utilisation in mental health. Our dataset contains 93,302 hospital episodes by 65,908 adult patients across 2114 municipalities. We estimate a random-effects spatial autoregressive combined model to regress log hospital admission rates on hospital supply and urbanicity as proxies for municipality healthcare service mix alongside demographic and socioeconomic controls. We find that admissions for depression are substantially higher in suburban municipalities compared to rural areas and in municipalities with hospitals compared to those without. The spatial structure suggests positive spatial spillovers between neighbouring municipalities. Our main results are stable across virtually all model specifications used for robustness and show that healthcare service mix and supply of hospital services strongly correlate with spatial patterns of hospital admission rates in the population. Promoting timely access to high-quality primary care and early-stage treatments may reduce the burden of avoidable depression-related hospitalisations for patients and public budgets, and close a gap of unmet need for care of vulnerable populations
Cost-sharing is a prominent tool in many healthcare systems, both for raising revenue and steering patient behaviour. Although the effect of cost-sharing on demand for healthcare services has been heavily studied in the literature, researchers often apply a macro-perspective to these issues, opening the door for policy makers to the fallacy of assuming uniform demand reactions across a spectrum of different forms of treatments and diagnostic procedures. We use a simple classification system to categorize 11 such healthcare services along the dimensions of urgency and price to estimate patients’ (anticipatory) demand reactions to a reduction in the co-insurance rate by a sickness fund in the Austrian social health insurance system. We use a two-stage study design combining matching and two-way fixed effects difference-in-differences estimation. Our results highlight how an overall joint estimate of an average increase in healthcare service utilization (0.8%) across all healthcare services can be driven by healthcare services that are deferrable (+1%), comparatively costly (+1.4%) or both (+1.6%) and for which patients also postponed their consumption until after the cost-sharing reduction. In contrast, we do not find a clear demand reaction for inexpensive or urgent services. The detailed analysis of the demand reaction for each individual healthcare service further illustrates their heterogeneity. We show that even comparatively minor changes to the costs borne by patients may already evoke tangible (anticipatory) demand reactions. Our findings help policy makers better understand the implications of heterogeneous demand reactions across healthcare services for using cost-sharing as a policy tool.
SSM - Population Health, 24, 101550 (2023)
Understanding the emergence of and changes in socioeconomic inequalities in lifespan requires reliable, longitudinal data. In the absence of administrative data, published obituaries may be one such alternative source. With the validity of drawing relevant data from obituaries not yet established in population health research, this study addresses this gap by estimating socioeconomic inequalities in lifespan in Vorarlberg, Austria. Data for all individuals (n = 1490) with obituaries published (July to December 2022) in a regional newspaper (market share: 56%) were extracted, including different markers of the deceased's socioeconomic status. Linear regression analyses showed that, on average, individuals with medium-sized obituaries lived 6.02 years (95% CI: 4.19, 7.85) and individuals with the largest obituaries 12.04 years (95% CI: 7.04, 17.04) longer than individuals with small obituaries while blue-collar workers lived 10.50 years (95% CI: -14.51, -6.49) shorter than individuals with no occupation (reported). This socioeconomic gradient is in line with findings based on national data sources, and comparisons with official regional data are promising regarding data representativeness and completeness. With obituary size reflecting different costs (€210–€1626) and thus being a novel marker for financial ability, obituaries could also be a useful, innovative data source internationally for historical analyses or “nowcasting” health inequalities.
International Journal of Health Economics and Management, 23, 149–172 (2023)
Increasing expenditures on retail pharmaceuticals bring a critical challenge to the financial stability of healthcare systems worldwide. Policy makers have reacted by introducing a range of measures to control the growth of public pharmaceutical expenditure (PPE). Using panel data on European and non-European OECD member countries from 1990-2015, we evaluate the effectiveness of six types of demand-side expenditure control measures including physician-level behavioural measures, system-level price-control measures and substitution measures, alongside a proxy for cost-sharing and add a new dimension to the existing empirical evidence hitherto based on national-level and meta-studies. We use the weighted-average least squares regression framework adapted for estimation with panel-corrected standard errors. Our empirical analysis suggests that direct patient cost-sharing and some - but not all - demand-side measures successfully dampened PPE growth in the past. Cost-sharing schemes stand out as a powerful mechanism to curb PPE growth, but bear a high risk of adverse effects. Other demand-side measures are more limited in effect, though may be more equitable. Due to limitations inherent in the study approach and the data, the results are only explorative.
Wiener Klinische Wochenschrift (The Central European Journal of Medicine), published online (2022)
Decision making in public health often happens against the background of scarce resources. The systematic use of economic evaluations can be a main enabler in the alignment of public health goals with budgetary constraints. However, the lack of standardized methodology in terms of costing method and perspective are a critical barrier to the implementation of economic evaluations and the international comparability of results. We present a novel set of of 22 reference unit costs (RUCs) optimized for cross-sectoral economic evaluations in Austria suitable for international comparability calculated using the standardized PECUNIA RUC Template. The common framework for costing and reporting, as well as the easy availability of the RUCs will reduce the burden on researchers and policy makers in future economic evaluations. The higher quality, accuracy, transparency and availability of economic evidence for policy design will help to improve the efficiency of public health-relevant healthcare decisions and make it easier for policy makers to bring funding arrangements and decision making across multiple sectors in line with Health-in-All-Policies goals.
European Journal of Health Economics, 22(6), 917-929 (2021)
Magnetic resonance imaging (MRI) is a popular yet cost-intensive diagnostic measure whose strengths compared to other medical imaging technologies have led to increased application. But the benefits of aggressive testing are doubtful. The comparatively high MRI usage in Austria in combination with substantial regional variation has hence become a concern for its policy makers. We use a set of routine healthcare data on outpatient MRI service consumption of Austrian patients between Q3-2015 and Q2-2016 on the district level to investigate the extent of medical practice variation in a two-step statistical analysis combining multivariate regression models and Blinder–Oaxaca decomposition. District-level MRI exam rates per 1.000 inhabitants range from 52.38 to 128.69. Controlling for a set of regional characteristics in a multivariate regression model, we identify payer autonomy in regulating access to MRI scans as the biggest contributor to regional variation. Nevertheless, the statistical decomposition highlights that more than 70% of the regional variation remains unexplained by differences between the observable district characteristics. In the absence of epidemiological explanations, the substantial regional medical practice variation calls the efficiency of resource deployment into question.
Social Science & Medicine , 249, 112855 (2020)
Soft budget constraints (SBCs) undermine reforms to increase hospital service efficiency when hospital management can count on being bailed out by (subnational) governments in case of deficits. Using cost accounting data on publicly financed, non-profit hospitals in Austria from 2002 to 2015, we analyse the association between SBCs and hospital efficiency change in a setting with negligible risk of hospital closure in a two-stage study design based on bias-corrected non-radial input-oriented data envelopment analysis and ordinary least squares regression. We find that the European debt crisis altered the pattern of hospital efficiency development: after the economic crisis, hospitals in low-debt states had a 1.1 percentage point lower annual efficiency change compared to hospitals in high-debt states. No such systematic difference is found before the economic crisis. The results suggest that sudden exogenous shocks to public finances can increase the budgetary pressure on publicly financed institutions, thereby counteracting a pre-existing SBC.
ORCID: 0000-0002-1183-8410 | Google Scholar: Michael Berger | Medical University of Vienna: Researcher Profile